TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial
Background M6223 is an intravenous (IV), Fc-competent, fully human, antagonistic, anti-T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) antibody. Bintrafusp alfa (BA) is a bifunctional fusion protein that simultaneously blocks nonredundant...
Saved in:
Main Authors: | Wei Gao, Ping Hu, Aung Naing, Meredith McKean, Anthony Tolcher, Lillian L Siu, Keyvan Tadjalli-Mehr, Anja Victor, Emilia Richter, Marco A F Nogueira Filho, Thomas Kitzing, Stephan Gleicher, Daniel Holland |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-02-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/2/e010584.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research on coupling evacuation of escalator and staircase in fire scenario.
by: Chunhua Zhang, et al.
Published: (2025-01-01) -
Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
by: Nayana Hitesh Patel, et al.
Published: (2023-04-01) -
Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
Published: (2023-07-01) -
NAPTUNE: nucleic acids and protein biomarkers testing via ultra-sensitive nucleases escalation
by: Tao Hu, et al.
Published: (2025-02-01) -
Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
by: November McGarvey, et al.
Published: (2015-11-01)